Cogent Biosciences, Inc. (COGT)
| Previous Close | 6.01 |
| Open | 6.02 |
| Bid | 6.00 x 100 |
| Ask | 6.02 x 100 |
| Day's Range | 5.95 - 6.16 |
| 52 Week Range | 3.67 - 13.50 |
| Volume | |
| Avg. Volume | 2,167,190 |
| Market Cap | 575.593M |
| Beta (5Y Monthly) | -0.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.42 |
| Earnings Date | May 07, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.70 |
GlobeNewswireCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki
- GuruFocus.com
COGT Reports Full Year 2023 Financial Results and Business Highlights
Bezuclastinib Trials Progress as Cogent Biosciences Inc. Strengthens Cash Position
- GlobeNewswire
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
• SUMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected by YE 2025• PEAK Phase 3 study of bezuclastinib + sunitinib in 2nd-line GIST patients on track to complete enrollment by end of 2024; topline results expected by YE 2025• APEX Part 2 registration-directed study of bezuclastinib in AdvSM patients on track to complete enrollment by end of 2024; topline
